Target intelligence / Profile preview

26S proteasome regulatory subunit ATPase 4 (human gene PSMC4; yeast ortholog Rpt4) (PSMC4 (Rpt4))

Target
PSMC4 (Rpt4)
Molecular classification
Enzyme, AAA+ ATPase, Ubiquitin–proteasome system component, Proteasome regulatory particle subunit (19S RP, base)
01

Overview

PSMC4 encodes Rpt4, one of six distinct AAA+ ATPase subunits (Rpt1–Rpt6) forming the heterohexameric motor in the 19S regulatory particle (RP, PA700) of the 26S proteasome. The 26S proteasome comprises a 20S core particle (CP) that houses proteolytic active sites and a 19S RP that recognizes polyubiquitylated substrates, removes ubiquitin (via Rpn11), unfolds substrates, opens the 20S α-ring gate, and translocates polypeptides into the CP. The AAA+ motor’s subunits, including Rpt4/PSMC4, bind and hydrolyze ATP in a coordinated, staircase-like cycle to power substrate unfolding/translocation; their C‑terminal tails engage α-ring pockets (HbYX-mediated interactions) to open the gate and couple mechanical work to proteolysis. Structural studies in yeast and human proteasomes have resolved distinct conformational states (e.g., s1–s4) and nucleotide occupancy patterns among Rpt subunits, highlighting specialized features such as ADP-bound Rpt6 and variable pore-loop positions that orchestrate substrate processing. As an essential component of the UPS, PSMC4 participates in regulating cell cycle, transcription, DNA replication, signaling, and stress responses; dysfunction or inhibition of the proteasome impacts cancer biology, neurodegeneration, infection, and immunity.

Other names
Proteasome 26S subunit, ATPase, 4Rpt426S proteasome AAA-ATPase subunit 4Regulatory particle triple-A ATPase subunit 419S regulatory particle ATPase subunit 4Proteasome subunit PSMC4
02

Mechanism of action

Proteasome inhibitors: reversible or irreversible inhibition of the 20S proteolytic active sites (chymotrypsin-like, etc.), leading to accumulation of ubiquitylated proteins and secondary inhibition of the 19S AAA+ ATPase-driven processing cycle that includes PSMC4. Experimental tool compounds and mechanistic insights indicate that ATP hydrolysis by the heterohexameric AAA+ ring (Rpt1–Rpt6 including Rpt4/PSMC4) drives substrate unfolding/translocation; modulation of nucleotide states alters conformational cycling and gate opening.

03

Biological functions

Protein quality control and regulated protein degradation via the ubiquitin–proteasome systemATP-dependent substrate unfolding and translocation into the 20S core particleGating control of the 20S core via C‑terminal tail insertion (HbYX motif) from ATPase subunits to open the α-ring gateCoordination of conformational states of the proteasome during substrate recruitment, deubiquitylation (Rpn11 activation), and processing
04

Disease associations

Cancer (proteasome activity is essential for tumor cell survival; proteasome inhibitors are approved anticancer therapies targeting the 26S proteasome complex)Neurodegenerative disease (UPS dysfunction implicated in proteostasis defects)Infection and immune regulation (antigen processing and immune responses rely on proteasomal degradation)Other: cardiovascular and stress-response pathways modulated through proteasomal turnover
05

Safety considerations

Systemic proteasome inhibition causes class toxicities: peripheral neuropathy, myelosuppression, gastrointestinal effects, and cardiotoxicity; these arise from inhibiting the essential UPS across tissuesSelective targeting of individual ATPase subunits like PSMC4 could risk broad cytotoxicity due to the essential nature of the ATPase motor for proteostasis
06

Interacting drugs

Bortezomib

3 more in the full profile.

07

Biomarkers

Proteasome activity assays or levels of polyubiquitylated proteins as pharmacodynamic markers for proteasome inhibitor therapyExpression/activity of 26S proteasome subunits (including ATPase subunits) explored as prognostic markers in some cancers; clinical validation is context-dependent and not specific to PSMC4 alone

Beyond the preview

Go deeper on 26S proteasome regulatory subunit ATPase 4 (human gene PSMC4; yeast ortholog Rpt4) (PSMC4 (Rpt4)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26S proteasome regulatory subunit ATPase 4 (human gene PSMC4; yeast ortholog Rpt4) (PSMC4 (Rpt4)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call